Curaleaf Holdings (OTC) (CURLF)
OTHER OTC:CURLF
Want to see CURLF full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.06Last Year’s EPS
-0.06Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presented several meaningful financial and strategic positives: revenue growth, a move to net income, strong international expansion (+35% YoY), improved adjusted EBITDA and gross margin levels, successful refinancing and balance sheet progress, and a major regulatory catalyst with medical rescheduling that could materially improve tax treatment, banking access, and international opportunities. These positives are tempered by margin compression (notably in international markets), a modest YoY decline in adjusted EBITDA, SG&A increases, inventory-driven low free cash flow in the quarter, and ongoing supply-chain and market-specific headwinds in select U.S. states. On balance, the company highlighted clear operational improvements, product initiatives driving transaction growth, and significant regulatory upside that management expects to unlock, outweighing the current operational and margin challenges.Company Guidance
Revenue Growth
Total Q1 2026 revenue of $324 million, up 6% year-over-year and above guidance; company expects Q2 revenue to rise 2%–3% sequentially (~$333M at midpoint).
International Outperformance
Curaleaf International revenue grew 35% year-over-year, outpacing domestic growth and beating internal plans; management cites momentum in Germany and the U.K.
Profitability Turnaround
Net income from continuing operations of $70 million, or $0.09 per share, versus a net loss of $50 million (−$0.09) in the year-ago period, reflecting a material swing to profitability.
Strong Adjusted EBITDA and Gross Margin
Adjusted EBITDA of $63 million representing a 20% margin; gross profit of $157 million and a 49% gross margin for the quarter.
Wholesale and Retail Execution
Domestic wholesale grew 19% year-over-year; Florida retail transaction count increased ~15% year-over-year following product and assortment changes, offsetting price compression in that market.
Balance Sheet and Financing Improvements
Ended quarter with $106 million cash; reduced acquisition-related debt by $9 million; refinanced a $475M senior secured note with an oversubscribed $500M three-year facility, signaling investor demand.
Strategic International Consolidation
Completed buyout of remaining 45% minority interest in German subsidiary Four 20 Pharma, bringing Curaleaf International to 100% ownership; implied Curaleaf International value ~ $1 billion based on a comparable transaction.
Regulatory Tailwinds — Rescheduling
Federal rescheduling of medical cannabis from Schedule I to Schedule III announced; potential material benefits include retroactive 280E tax relief (60% of business is medical), ability to apply for DEA licenses (company filed applications), expanded research, and improved banking/credit access.
Operational and Product Initiatives
Launched BRIC 2 and Dark Heart (ultra-premium flower) and began rolling Built for Growth playbook across markets (customer centricity, operational excellence, brand building), helping stabilize pricing and drive units/traffic.
Audit and Governance Upgrade
Transitioned independent audit partner to BDO to strengthen transparency and oversight ahead of potential U.S. exchange uplisting.
CURLF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CURLF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 05, 2026 | $3.48 | $3.81 | +9.43% |
Feb 26, 2026 | $2.43 | $2.33 | -4.23% |
Nov 05, 2025 | $2.85 | $2.43 | -14.74% |
Aug 06, 2025 | $1.68 | $1.79 | +6.55% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Curaleaf Holdings (OTC) (CURLF) report earnings?
Curaleaf Holdings (OTC) (CURLF) is schdueled to report earning on Aug 12, 2026, After Close (Confirmed).
What is Curaleaf Holdings (OTC) (CURLF) earnings time?
Curaleaf Holdings (OTC) (CURLF) earnings time is at Aug 12, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CURLF EPS forecast?
CURLF EPS forecast for the fiscal quarter 2026 (Q2) is -0.06.
